Akebia Therapeutics, Inc.(NASDAQ : AKBA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.45%||166.93||0.7%||$1253.55m|
|LLY||Eli Lilly & Co.||0.18%||311.43||1.1%||$814.08m|
|BMY||Bristol-Myers Squibb Co.||-0.73%||70.77||1.0%||$778.85m|
|MRK||Merck & Co., Inc.||-0.81%||86.80||0.7%||$691.58m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-0.95%||200.78||8.2%||$207.03m|
|GBT||Global Blood Therapeutics, Inc.||0.03%||67.99||5.4%||$199.71m|
|NVO||Novo Nordisk A/S||-0.40%||97.92||0.1%||$170.11m|
|HZNP||Horizon Therapeutics Plc||0.54%||62.97||5.4%||$156.21m|
|SRPT||Sarepta Therapeutics, Inc.||-2.42%||108.19||12.4%||$128.76m|
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.